Published • loading... • Updated
AstraZeneca Strikes $40 Million AI Drug Discovery Deal with Insitro
The multi-year deal gives insitro $40 million upfront and could pay about $1.46 billion in milestones and royalties.
- On Thursday, AstraZeneca partnered with California-based biotech company Insitro to discover and develop treatments for MASH and cardiomyopathies, complex diseases affecting the liver and heart muscle.
- Researchers have historically struggled to pinpoint root biological drivers for these complex diseases, prompting AstraZeneca to seek new approaches after failing in mid-stage MASH trials last year.
- Under the agreement, AstraZeneca will pay $40 million upfront, with Insitro eligible for about $1.5 billion in potential development and commercial milestones, plus single-digit royalties.
- Insitro will apply its "Virtual Human" AI platform to identify causal disease biology and advance targets to development-candidate stage, while AstraZeneca will run and fund all future clinical trials.
- CEO Daphne Koller said Insitro focuses on early-stage discovery, recently expanding partnerships with Bristol Myers Squibb for ALS research and Eli Lilly for AI modeling of molecular properties.
Insights by Ground AI
11 Articles
11 Articles
AstraZeneca taps 'Virtual Human' AI in $1.5 billion deal to develop liver, heart disease drugs
AstraZeneca will pay insitro $40 million upfront, with up to $1.46 billion in milestone payments, to use its Virtual Human AI platform to develop treatments for liver and heart diseases.
·Mumbai, India
Read Full Article
AstraZeneca strikes $40 million AI drug discovery deal with ...
·London, United Kingdom
Read Full Article
AstraZeneca and Insitro Ink $1.86 Billion AI Drug Discovery Deal
AstraZeneca Plc is collaborating with machine learning biotech Insitro Inc. in a deal worth as much as $1.86 billion intended to help the British drugmaker find new medicines for the liver and heart.
·New York, United States
Read Full Article
Pharmaceutical company Astra Zeneca has signed a licensing agreement with the company Insitro, which will receive $40 million in an immediate one-time payment and the possibility of receiving up to approximately $1.46 billion in development and commercial milestones plus single-digit royalties.
Coverage Details
Total News Sources11
Leaning Left0Leaning Right3Center5Last UpdatedBias Distribution63% Center
Bias Distribution
- 63% of the sources are Center
63% Center
C 63%
R 37%
Factuality
To view factuality data please Upgrade to Premium
